A detailed history of Sigma Planning Corp transactions in Cue Biopharma, Inc. stock. As of the latest transaction made, Sigma Planning Corp holds 401,325 shares of CUE stock, worth $433,431. This represents 0.01% of its overall portfolio holdings.

Number of Shares
401,325
Previous 266,030 50.86%
Holding current value
$433,431
Previous $329,000 7.29%
% of portfolio
0.01%
Previous 0.01%

Shares

23 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 01, 2024

BUY
$0.45 - $1.08 $60,882 - $146,118
135,295 Added 50.86%
401,325 $305,000
Q2 2024

Aug 05, 2024

BUY
$1.24 - $2.18 $12,431 - $21,854
10,025 Added 3.92%
266,030 $329,000
Q1 2024

May 01, 2024

BUY
$1.77 - $3.09 $260,420 - $454,631
147,130 Added 135.14%
256,005 $483,000
Q4 2023

Feb 01, 2024

SELL
$1.72 - $3.1 $233,627 - $421,073
-135,830 Reduced 55.51%
108,875 $287,000
Q3 2023

Nov 06, 2023

BUY
$2.23 - $4.69 $43,273 - $91,009
19,405 Added 8.61%
244,705 $562,000
Q2 2023

Aug 01, 2023

BUY
$3.11 - $4.91 $13,718 - $21,658
4,411 Added 2.0%
225,300 $822,000
Q1 2023

May 05, 2023

BUY
$2.41 - $3.74 $67,853 - $105,299
28,155 Added 14.61%
220,889 $788,000
Q4 2022

Jan 24, 2023

BUY
$2.39 - $3.95 $10,300 - $17,024
4,310 Added 2.29%
192,734 $0
Q3 2022

Nov 10, 2022

BUY
$2.23 - $3.37 $47,539 - $71,841
21,318 Added 12.76%
188,424 $420,000
Q2 2022

Aug 11, 2022

BUY
$2.49 - $5.92 $93,071 - $221,277
37,378 Added 28.81%
167,106 $416,000
Q1 2022

Apr 20, 2022

BUY
$4.41 - $12.28 $193,312 - $538,293
43,835 Added 51.03%
129,728 $633,000
Q4 2021

Feb 02, 2022

BUY
$10.86 - $17.85 $17,919 - $29,452
1,650 Added 1.96%
85,893 $971,000
Q3 2021

Oct 28, 2021

BUY
$10.06 - $15.3 $25,572 - $38,892
2,542 Added 3.11%
84,243 $1.23 Million
Q2 2021

Aug 13, 2021

BUY
$10.9 - $14.53 $93,881 - $125,146
8,613 Added 11.78%
81,701 $952,000
Q1 2021

May 06, 2021

BUY
$11.2 - $16.09 $16,934 - $24,328
1,512 Added 2.11%
73,088 $892,000
Q4 2020

Feb 09, 2021

BUY
$11.12 - $16.4 $130,693 - $192,749
11,753 Added 19.65%
71,576 $895,000
Q3 2020

Nov 03, 2020

BUY
$15.05 - $23.54 $101,497 - $158,753
6,744 Added 12.71%
59,823 $900,000
Q2 2020

Jul 31, 2020

SELL
$12.7 - $30.73 $167,208 - $404,591
-13,166 Reduced 19.87%
53,079 $1.3 Million
Q1 2020

May 01, 2020

BUY
$9.85 - $22.27 $8,717 - $19,708
885 Added 1.35%
66,245 $940,000
Q4 2019

Feb 03, 2020

BUY
$7.06 - $17.47 $36,359 - $89,970
5,150 Added 8.55%
65,360 $1.04 Million
Q3 2019

Nov 01, 2019

BUY
$6.78 - $9.28 $84,105 - $115,118
12,405 Added 25.95%
60,210 $508,000
Q2 2019

Aug 01, 2019

BUY
$7.18 - $9.65 $40,969 - $55,062
5,706 Added 13.55%
47,805 $430,000
Q1 2019

May 01, 2019

BUY
$4.7 - $9.29 $197,865 - $391,099
42,099 New
42,099 $325,000

Others Institutions Holding CUE

About Cue Biopharma, Inc.


  • Ticker CUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 35,381,700
  • Market Cap $38.2M
  • Description
  • Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target an...
More about CUE
Track This Portfolio

Track Sigma Planning Corp Portfolio

Follow Sigma Planning Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

News

Stay updated on Sigma Planning Corp with notifications on news.